Advertisement

Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona

Published:October 21, 2017DOI:https://doi.org/10.1016/j.ejca.2017.09.021

      Highlights

      • Review about the current status of various molecular tests for GI cancers and especially considering their significance for the clinical routine use.
      • Opinion leaders and experts from diverse nationalities participated in the discussion.
      • The clearly and comprehensibly formulated guidelines assist clinicians in the process of making treatment choices in daily clinical practice.

      Abstract

      Background and scope

      In the epoch of precision medicine and personalised oncology, which aims to deliver the right treatment to the right patient, molecular genetic biomarkers are a topic of growing interest. The aim of this expert discussion and position paper is to review the current status of various molecular tests for gastrointestinal (GI) cancers and especially considering their significance for the clinical routine use.

      Methodology

      Opinion leaders and experts from diverse nationalities selected on scientific merit were asked to answer to a prepared set of questions about the current status of molecular diagnostics in different GI cancers. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both clinical expertise and updated evidence-based medicine.

      Results

      Preselected molecular genetic biomarkers that are described and disputed in the current medical literature in different GI cancers were debated, and recommendations for clinical routine practice were made whenever possible. Furthermore, the preanalytical variations were commented and proposals for quality controls of biospecimens were made.

      Conclusion

      The current article summarises the recommendations of the expert committee regarding prognostic and predictive molecular genetic biomarkers in different entities of GI cancers. The briefly and comprehensively formulated guidelines should assist clinicians in the process of decision making in daily clinical practice.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bang Y.J.
        • Van Cutsem E.
        • Feyereislova A.
        • Chung H.C.
        • Shen L.
        • Sawaki A.
        • et al.
        • ToGA Trial Investigators
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet. 2010; 28; 376: 687-697
        • Lee H.E.
        • Park K.U.
        • Yoo S.B.
        • Nam S.K.
        • Park do J.
        • Kim H.H.
        • et al.
        Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
        Eur J Cancer. 2013; 49: 1448-1457
        • Ruschoff J.
        • Nagelmeier I.
        • Baretton G.
        • Dietel M.
        • Hofler H.
        • Schildhaus H.U.
        • et al.
        Her2 testing in gastric cancer. What is different in comparison to breast cancer?.
        Pathologe. 2010; 31: 208-217
        • Kim M.A.
        • Lee H.J.
        • Yang H.K.
        • Bang Y.J.
        • Kim W.H.
        Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma.
        Histopathology. 2011; 59: 822-831
        • Lee S.
        • de Boer W.B.
        • Fermoyle S.
        • Platten M.
        • Kumarasinghe M.P.
        Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and re-sections.
        Histopathology. 2011; 59: 832-840
        • Park S.R.
        • Park Y.S.
        • Ryu M.H.
        • Ryoo B.Y.
        • Woo C.G.
        • Jung H.Y.
        • et al.
        Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
        Eur J Cancer. 2016; 53: 42-50
        • Gullo I.
        • Grillo F.
        • Molinaro L.
        • Fassan M.
        • De Silvestri A.
        • Tinelli C.
        • et al.
        Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer.
        Endosc Int Open. 2015 Apr; 3: E165-E170
        • Lordick F.
        • Al-Batran S.E.
        • Dietel M.
        • Gaiser T.
        • Hofheinz R.D.
        • Kirchner T.
        • et al.
        HER2 testing in gastric cancer: results of a German expert meeting.
        J Cancer Res Clin Oncol. 2017 May; 143: 835-841
        • Shoda K.
        • Masuda K.
        • Ichikawa D.
        • Arita T.
        • Miyakami Y.
        • Watanabe M.
        • et al.
        HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study.
        Gastric Cancer. 2015 Oct; 18: 698-710
        • Shoda K.
        • Ichikawa D.
        • Fujita Y.
        • Masuda K.
        • Hiramoto H.
        • Hamada J.
        • et al.
        Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.
        Gastric Cancer. 2017 Jan; 20: 126-135
        • Oyama K.
        • Fushida S.
        • Tsukada T.
        • Kinoshita J.
        • Watanabe T.
        • Shoji M.
        • et al.
        Evaluation of serum HER2-ECD levels in patients with gastric cancer.
        J Gastroenterol. 2015 Jan; 50: 41-45
        • Shimada H.
        Is “liquid biopsy” useful for assessing HER2 status in gastric cancer?.
        J Gastroenterol. 2015 Jan; 50: 119-120
        • Kinugasa H.
        • Nouso K.
        • Tanaka T.
        • Miyahara K.
        • Morimoto Y.
        • Dohi C.
        • et al.
        Droplet digital PCR measurement of HER2 in patients with gastric cancer.
        Br J Cancer. 2015 May 12; 112: 1652-1655
        • Cancer Genome Atlas Research Network
        Comprehensive molecular characterization of gastric adenocarcinoma.
        Nature. 2014; 513: 202-209
        • Cristescu R.
        • Lee J.
        • Nebozhyn M.
        • Kim K.M.
        • Ting J.C.
        • Wong S.S.
        • et al.
        Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
        Nat Med. 2015; 21: 449-456
        • Smyth E.C.
        • Wotherspoon A.
        • Peckitt C.
        • Gonzalez D.
        • Hulkki-Wilson S.
        • Eltahir Z.
        • et al.
        Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial.
        JAMA Oncol. 2017 Feb 23; https://doi.org/10.1001/jamaoncol.2016.6762
        • Cho J.
        • Lee J.
        • Bang H.
        • Kim S.T.
        • Park S.H.
        • An J.Y.
        • et al.
        Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
        Oncotarget. 2017 Feb 21; 8: 13320-13328
        • Derks S.
        • Liao X.
        • Chiaravalli A.M.
        • Xu X.
        • Camargo M.C.
        • Solcia E.
        • et al.
        Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
        Oncotarget. 2016; 7: 32925-32932
        • Shia J.
        Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.
        J Mol Diagn. 2008; 10: 293-300
        • Gu L.
        • Chen M.
        • Guo D.
        • Zhu H.
        • Zhang W.
        • Pan J.
        • et al.
        PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis.
        PLoS One. 2017 Aug 10; 12e0182692
        • Chen X.Z.
        • Chen H.
        • Castro F.A.
        • Hu J.K.
        • Brenner H.
        Epstein-Barr virus infection and gastric cancer: a systematic review.
        Medicine (Baltimore). 2015 May; 94e792
        • Allison J.P.
        Immune checkpoint blockade in cancer therapy: the 2015 Lasker-DeBakey Clinical Medical Research Award.
        JAMA. 2015; 314: 1113-1114
        • Ohaegbulam K.C.
        • Assal A.
        • Lazar-Molnar E.
        • Yao Y.
        • Zang X.
        Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
        Trends Mol Med. 2015; 21: 24-33
        • Scheel A.H.
        • Dietel M.
        • Heukamp L.C.
        • Jöhrens K.
        • Kirchner T.
        • Reu S.
        • et al.
        Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
        Mod Pathol. 2016 Oct; 29: 1165-1172
        • Hutarew G.
        PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.
        Memo. 2016; 9: 201-206
        • Muro K.
        • Chung H.C.
        • Shankaran V.
        • Geva R.
        • Catenacci D.
        • Gupta S.
        • et al.
        Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
        Lancet Oncol. 2016 Jun; 17: 717-726
        • Fuchs S.C.
        • Doi T.
        • Jang R.
        • Muro K.
        • Satoh T.
        • Machado M.
        • et al.
        KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
        J Clin Oncol. 2017; 35 (suppl; abstr 4003)
        • Dienstmann R.
        • Rodon J.
        • Prat A.
        • Perez-Garcia J.
        • Adamo B.
        • Felip E.
        • et al.
        Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
        Ann Oncol. 2014; 25: 552-563
        • Betts G.
        • Valentine H.
        • Pritchard S.
        • Swindell R.
        • Williams V.
        • Morgan S.
        • et al.
        FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
        Virchows Arch. 2014; 464: 145-156
        • Su X.
        • Zhan P.
        • Gavine P.R.
        • Morgan S.
        • Womack C.
        • Ni X.
        • et al.
        FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
        Br J Cancer. 2014; 110: 967-975
        • Thrift A.P.
        • Nagle C.M.
        • Fahey P.P.
        • Russell A.
        • Smithers B.M.
        • Watson D.I.
        • et al.
        The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival.
        Int J Cancer. 2012; 131: E759-E768
        • Mandard A.M.
        • Hainaut P.
        • Hollstein M.
        Genetic steps in the development of squamous cell carcinoma of the esophagus.
        Mutat Res. 2000; 462: 335-342
        • Doi T.
        • Piha-Paul S.A.
        • Jalal S.I.
        • Mai-Dang H.
        • Saraf S.
        • Koshiji M.
        • et al.
        Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475).
        J Clin Oncol. 2016; 34 (7–7)
        • Kudo T.
        • Hamamoto Y.
        • Kato K.
        • Ura T.
        • Kojima T.
        • Tsushima T.
        • et al.
        Nivolumab treatment for oesophageal squamouscell carcinoma: an open-label, multicentre, phase 2 trial.
        Lancet Oncol. 2017; 18: 631-639
        • Matsumoto K.
        • Nakamura T.
        • Sakai K.
        • Nakamura T.
        Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
        Proteomics. 2008; 8: 3360-3370
        • Maroun C.R.
        • Rowlands T.
        The met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
        Pharmacol Ther. 2014; 142: 316-338
        • Santoro A.
        • Rimassa L.
        • Borbath I.
        • Daniele B.
        • Salvagni S.
        • Van Laethem J.L.
        • et al.
        Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
        Lancet Oncol. 2013 Jan; 14: 55-63
        • Okuma H.S.
        • Kondo S.
        Trends in the development of MET inhibitors for hepatocellular carcinoma.
        Future Oncol. 2016 May; 12: 1275-1286
        • Rimassa L.
        • Assenat E.
        • Peck-Radosavljevic M.
        • Zagonel V.
        • Pracht M.
        • Caremoli E.R.
        • et al.
        Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): results of the METIV-HCC phase III trial.
        JCO. May 2017; 35 (4000–4000)
        • Prieto J.
        • Melero I.
        • Sangro B.
        Immunological landscape and immunotherapy of hepatocellular carcinoma.
        Nat Rev Gastroenterol Hepatol. 2015; 12: 681-700
        • El-Khoueiry A.B.
        • Sangro B.
        • Yau T.
        • Crocenzi T.S.
        • Kudo M.
        • Hsu C.
        • et al.
        Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
        Lancet. 2017 Jun 24; 389: 2492-2502
        • Nakamura H.
        • Arai Y.
        • Totoki Y.
        • Shirota T.
        • Elzawahry A.
        • Kato M.
        • et al.
        Genomic spectra of biliary tract cancer.
        Nat Genet. 2015; 47: 1003-1010
        • Chong D.Q.
        • Zhu A.X.
        The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
        Oncotarget. 2016 Jul 19; 7: 46750-46767
        • Verlingue L.
        • Hollebecque A.
        • Boige V.
        • Ducreux M.
        • Malka D.
        • Ferté C.
        Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground?.
        Eur J Cancer. 2017 Jun 16; 81: 161-173
        • Grassian A.R.
        • Pagliarini R.
        • Chiang D.Y.
        Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
        Curr Opin Gastroenterol. 2014; 30: 295-302
        • Borger D.R.
        • Tanabe K.K.
        • Fan K.C.
        • Lopez H.U.
        • Fantin V.R.
        • Straley K.S.
        • et al.
        Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
        Oncologist. 2012; 17: 72-79
        • Birchmeier C.
        • Birchmeier W.
        • Gherardi E.
        • Vande Woude G.F.
        Met, metastasis, motility and more.
        Nat Rev Mol Cell Biol. 2003; 4: 915-925
        • Peters S.
        • Adjei A.A.
        MET: a promising anticancer therapeutic target.
        Nat Rev Clin Oncol. 2012; 9: 314-326
        • Jardim D.L.
        • Tang C.
        • Gagliato Dde M.
        • Falchook G.S.
        • Hess K.
        • Janku F.
        • et al.
        Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
        Clin Cancer Res. 2014; 20: 6336-6345
        • Gherardi E.
        • Birchmeier W.
        • Birchmeier C.
        • Vande Woude G.
        Targeting MET in cancer: rationale and progress.
        Nat Rev Cancer. 2012; 12: 89-103
        • Marquardt J.U.
        • Andersen J.B.
        Next-generation sequencing: application in liver cancer-past, present and future?.
        Biology (Basel). 2012; 1: 383-394
        • Holter S.
        • Borgida A.
        • Dodd A.
        • Grant R.
        • Semotiuk K.
        • Hedley D.
        • et al.
        Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma.
        J Clin Oncol. 2015; 33: 3124-3129
        • Lowery M.A.
        • Kelsen D.P.
        • Stadler Z.K.
        • Yu K.H.
        • Janjigian Y.Y.
        • Ludwig E.
        • et al.
        An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation—clinical descriptors, treatment implications, and future directions.
        Oncologist. 2011; 16: 1397-1402
        • Golan T.
        • Kanji Z.S.
        • Epelbaum R.
        • Devaud N.
        • Dagan E.
        • Holter S.
        • et al.
        Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
        Br J Cancer. 2014; 111: 1132-1138
        • Kaufman B.
        • Shapira-Frommer R.
        • Schmutzler R.K.
        • Audeh M.W.
        • Friedlander M.
        • Balmaña J.
        • et al.
        Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
        J Clin Oncol. 2015; 33: 244-250
        • Kindler H.L.
        • Locker G.Y.
        • Mann H.
        • Golan T.
        POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy.
        J Clin Oncol. 2015; 33
      1. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: Breast and Ovarian (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

        • Bourgon R.
        • Lu S.
        • Yan Yibing
        • Lackner Mark R.
        • Wang Weiru
        • Weigman Victor
        • et al.
        High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
        April 2014https://doi.org/10.1158/1078-0432.CCR-13-3114
        • Dong X.
        • Li Y.
        • Chang P.
        • Hess K.R.
        • Abbruzzese J.L.
        • Li D.
        DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer.
        Mol Carcinog. 2012; 51: 491-499
        • Riazy M.
        • Kalloger S.E.
        • Sheffield B.S.
        • Peixoto R.D.
        • Li-Chang H.H.
        • Scudamore C.H.
        • et al.
        Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
        Mod Pathol. 2015; 28: 1383-1389
        • Kastrinos F.
        • Mukherjee B.
        • Tayob N.
        • Wang F.
        • Sparr J.
        • Raymond V.M.
        • et al.
        Risk of pancreatic cancer in families with Lynch syndrome.
        JAMA. 2009; 28; 302: 1790-1795
        • Grünewald K.
        • Lyons J.
        • Fröhlich A.
        • Feichtinger H.
        • Weger R.A.
        • Schwab G.
        • et al.
        High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.
        Int J Cancer. 1989; 43: 1037-1041
        • Almoguera C.
        • Shibata D.
        • Forrester K.
        • Martin J.
        • Arnheim N.
        • Perucho M.
        Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.
        Cell. 1988; 53: 549-554
        • Sanger Institute
        COSMIC: catalogue of somatic mutations in cancer.
        2016 ([Accessed August 2016])
        • Boland C.R.
        • Koi M.
        • Chang D.K.
        • Carethers J.M.
        The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside.
        Fam Cancer. 2008; 7: 41-52
        • Zhang C.M.
        • Lv J.F.
        • Gong L.
        • Yu L.Y.
        • Chen X.P.
        • Zhou H.H.
        • et al.
        Role of deficient mismatch repair in the personalized management of colorectal cancer.
        Int J Environ Res Public Health. 2016; 13: E892
        • Vilar E.
        • Gruber S.B.
        Microsatellite instability in colorectal cancer-the stable evidence.
        Nat Rev Clin Oncol. 2010; 7: 153-162
        • Lochhead P.
        • Kuchiba A.
        • Imamura Y.
        • Liao X.
        • Yamauchi M.
        • Nishihara R.
        • et al.
        Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
        J Natl Cancer Inst. 2013; 105: 1151-1156
        • Ribic C.M.
        • Sargent D.J.
        • Moore M.J.
        • Thibodeau S.N.
        • French A.J.
        • Goldberg R.M.
        • et al.
        Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
        N Engl J Med. 2003; 349: 247-257
        • Le D.T.
        • Uram J.N.
        • Wang H.
        • Bartlett B.R.
        • Kemberling H.
        • Eyring A.D.
        • et al.
        PD-1 blockade in tumors with mismatch-repair deficiency.
        N Engl J Med. 2015 Jun 25; 372: 2509-2520
        • Roberts P.J.
        • Der C.J.
        Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
        Oncogene. 2007; 26: 3291-3310
        • Lièvre A.
        • Bachet J.B.
        • Le Corre D.
        • Boige V.
        • Landi B.
        • Emile J.F.
        • et al.
        KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
        Cancer Res. 2006; 66: 3992-3995
        • De Roock W.
        • De Vriendt V.
        • Normanno N.
        • Ciardiello F.
        • Tejpar S.
        KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
        Lancet Oncol. 2011; 12: 594-603
        • Primrose J.
        • Falk S.
        • Finch-Jones M.
        • Valle J.
        • O'Reilly D.
        • Siriwardena A.
        • et al.
        Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
        Lancet Oncol. 2014 May; 15: 601-611
        • Tie J.
        • Wang Y.
        • Tomasetti C.
        • Li L.
        • Springer S.
        • Kinde I.
        • et al.
        Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
        Sci Transl Med. 2016 Jul 6; 8 (346ra92)
        • Schmiegel W.
        • Scott R.J.
        • Dooley S.
        • Lewis W.
        • Meldrum C.J.
        • Pockney P.
        • et al.
        Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
        Mol Oncol. 2017 Feb; 11: 208-219
        • Grasselli J.
        • Elez E.
        • Caratù G.
        • Matito J.
        • Santos C.
        • Macarulla T.
        • et al.
        Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
        Ann Oncol. 2017 Jun 1; 28: 1294-1301
        • Vidal J.
        • Muinelo L.
        • Dalmases A.
        • Jones F.
        • Edelstein D.
        • Iglesias M.
        • et al.
        Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
        Ann Oncol. 2017 Jun 1; 28: 1325-1332
        • Morelli M.P.
        • Overman M.J.
        • Dasari A.
        • Kazmi S.M.
        • Mazard T.
        • Vilar E.
        • et al.
        Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
        Ann Oncol. 2015; 26: 731-736
        • Siravegna G.
        • Mussolin B.
        • Buscarino M.
        • Corti G.
        • Cassingena A.
        • Crisafulli G.
        • et al.
        Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
        Nat Med. 2015; 21: 795-801
        • Thierry A.R.
        • Pastor B.
        • Jiang Z.Q.
        • Katsiampoura A.
        • Parseghian C.
        • Loree J.M.
        • et al.
        Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer.
        Clin Cancer Res. 2017 Apr 11; (pii: clincanres.0232.2017)https://doi.org/10.1158/1078-0432.CCR-17-0232
        • Cancer Genome Atlas Network
        Comprehensive molecular characterization of human colon and rectal cancer.
        Nature. 2012; 487: 330-337
        • Douillard J.Y.
        • Oliner K.S.
        • Siena S.
        • Tabernero J.
        • Burkes R.
        • Barugel M.
        • et al.
        Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
        N Engl J Med. 2013; 369: 1023-1034
        • Benson 3rd, A.B.
        • Venook A.P.
        • Cederquist L.
        • Chan E.
        • Chen Y.J.
        • Cooper H.S.
        • et al.
        Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2017 Mar; 15: 370-398
        • Van Cutsem E.
        • Cervantes A.
        • Adam R.
        • Sobrero A.
        • Van Krieken J.H.
        • Aderka D.
        • et al.
        ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
        Ann Oncol. 2016 Aug; 27: 1386-1422
        • Parsons M.T.
        • Buchanan D.D.
        • Thompson B.
        • Young J.P.
        • Spurdle A.B.
        Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
        J Med Genet. 2012; 49: 151-157
        • Martinelli E.
        • Morgillo F.
        • Troiani T.
        • Ciardiello F.
        Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK.
        Cancer Treat Rev. 2017 Feb; 53: 61-69
        • Jones J.C.
        • Renfro L.A.
        • Al-Shamsi H.O.
        • Schrock A.B.
        • Rankin A.
        • Zhang B.Y.
        • et al.
        Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer.
        J Clin Oncol. 2017 Aug 10; 35: 2624-2630
        • Sartore-Bianchi A.
        • Martini M.
        • Molinari F.
        • Veronese S.
        • Nichelatti M.
        • Artale S.
        • et al.
        PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
        Cancer Res. 2009; 69: 1851-1857
        • Mei Z.B.
        • Duan C.Y.
        • Li C.B.
        • Cui L.
        • Ogino S.
        Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
        Ann Oncol. 2016; 27: 1836-1848
        • Liao X.
        • Lochhead P.
        • Nishihara R.
        • Morikawa T.
        • Kuchiba A.
        • Yamauchi M.
        • et al.
        Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
        N Engl J Med. 2012; 367: 1596-1606
        • Takegawa N.
        • Yonesaka K.
        • Sakai K.
        • Ueda H.
        • Watanabe S.
        • Nonagase Y.
        • et al.
        Nakagawa K.HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
        Oncotarget. 2016; 7: 3453-3460
        • Bertotti A.
        • Migliardi G.
        • Galimi F.
        • Sassi F.
        • Torti D.
        • Isella C.
        • et al.
        A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
        Cancer Discov. 2011; 1: 508-523
        • Sartore-Bianchi A.
        • Trusolino L.
        • Martino C.
        • Bencardino K.
        • Lonardi S.
        • Bergamo F.
        • et al.
        Dual-targeted therapy with trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2016; 17: 738-746
        • Hurwitz H.
        • Hainsworth J.D.
        • Swanton C.
        • Perez E.A.
        • Sweeney C.
        • Burris H.A.
        • et al.
        Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.
        J Clin Oncol. 2016; 34 (abstr 653)
        • Pérez-Vargas J.C.
        • Biondani P.
        • Maggi C.
        • Gariboldi M.
        • Gloghini A.
        • Inno A.
        • et al.
        Role of cMET in the development and progression of colorectal cancer.
        Int J Mol Sci. 2013 Sep 3; 14: 18056-18077
        • Bardelli A.
        • Corso S.
        • Bertotti A.
        • Hobor S.
        • Valtorta E.
        • Siravegna G.
        • et al.
        Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
        Cancer Discov. 2013; 3: 658-673
        • Cully M.
        • You H.
        • Levine A.J.
        • Mak T.W.
        Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
        Nat Rev Cancer. 2006; 6: 184-192
        • Di Cristofano A.
        • Pandolfi P.P.
        The multiple roles of PTEN in tumor suppression.
        Cell. 2000; 100: 387-390
        • Atreya C.E.
        • Sangale Z.
        • Xu N.
        • Matli M.R.
        • Tikishvili E.
        • Welbourn W.
        • et al.
        PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
        Cancer Med. 2013; 2: 496-506
        • Guinney J.
        • Dienstmann R.
        • Wang X.
        • de Reyniès A.
        • Schlicker A.
        • Soneson C.
        • et al.
        The consensus molecular subtypes of colorectal cancer.
        Nat Med. 2015; 21: 1350-1356
        • Zaaimi Y.
        • Aparicio T.
        • Laurent-Puig P.
        • Taieb J.
        • Zaanan A.
        Advanced small bowel adenocarcinoma: molecular characteristics and therapeutic perspectives.
        Clin Res Hepatol Gastroenterol. 2016 Apr; 40: 154-160
        • Saslow D.
        • Solomon D.
        • Lawson H.W.
        • Killackey M.
        • Kulasingam S.L.
        • Cain J.
        • et al.
        American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
        CA Cancer J Clin. 2012; 62: 147-172
        • Shiels M.S.
        • Cole S.R.
        • Kirk G.D.
        • Poole C.
        A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals.
        J Acquir Immune Defic Syndr. 2009; 52: 611-622
        • Mai S.
        • Welzel G.
        • Ottstadt M.
        • Lohr F.
        • Severa S.
        • Prigge E.S.
        • et al.
        Prognostic relevance of HPV Infection and p16 overexpression in squamous cell anal cancer.
        Int J Radiat Oncol Biol Phys. 2015; 93: 819-827
        • Singer S.
        • Rubin B.P.
        • Lux M.L.
        • Chen C.J.
        • Demetri G.D.
        • Fletcher C.D.
        • et al.
        Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
        J Clin Oncol. 2002; 20: 3898-3905
        • Kikuchi H.
        • Miyazaki S.
        • Setoguchi T.
        • Hiramatsu Y.
        • Ohta M.
        • Kamiya K.
        • et al.
        Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene.
        Anticancer Res. 2012; 32: 4105-4109
        • Yan L.
        • Zou L.
        • Zhao W.
        • Wang Y.
        • Liu B.
        • Yao Hand
        • et al.
        Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis.
        Sci Rep. 2015; 5: 13718
        • Patrikidou A.
        • Domont J.
        • Chabaud S.
        • Ray-Coquard I.
        • Coindre J.M.
        • Bui-Nguyen B.
        • et al.
        • French Sarcoma Group
        Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
        Eur J Cancer. 2016 Jan; 52: 173-180
        • Wozniak A.
        • Rutkowski P.
        • Schöffski P.
        • Ray-Coquard I.
        • Hostein I.
        • Schildhaus H.U.
        • et al.
        Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.
        Clin Cancer Res. 2014 Dec 1; 20: 6105-6116
        • Yoo C.
        • Ryu M.H.
        • Jo J.
        • Park I.
        • Ryoo B.Y.
        • Kang Y.K.
        Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors.
        Cancer Res Treat. 2016 Apr; 48: 546-552
        • Miranda C.
        • Nucifora M.
        • Molinari F.
        • Conca E.
        • Anania M.C.
        • Bordoni A.
        • et al.
        KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
        Clin Cancer Res. 2012; 18: 1769-1776
        • Rossi S.
        • Sbaraglia M.
        • Dell'Orto M.C.
        • Gasparotto D.
        • Cacciatore M.
        • Boscato E.
        • et al.
        Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
        Oncotarget. 2016 May 24; 7: 30109-30118
        • David K.A.
        • Unger F.T.
        • Uhlig P.
        • Juhl H.
        • Moore H.M.
        • Compton C.
        • et al.
        Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue.
        Oncotarget. 2014 Nov 30; 5: 11017-11028
        • Unger F.T.
        • Lange N.
        • Krüger J.
        • Compton C.
        • Moore H.
        • Agrawal L.
        • et al.
        Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissue.
        J Transl Med. 2016 Jan 8; 14: 6https://doi.org/10.1186/s12967-015-0752-1
      2. https://biospecimens.cancer.gov/bestpractices/2016-NCIBestPractices.pdf.

      3. Bonnes pratiques pour la recherche à visée théranostique de mutations somatiques dans les tumeurssolides from Institut National du Cancer. 2010
        • Cree I.A.
        • Deans Z.
        • Ligtenberg M.J.
        • Normanno N.
        • Edsjö A.
        • Rouleau E.
        • et al.
        Guidance for laboratories performing molecular pathology for cancer patients.
        J Clin Pathol. 2014 Nov; 67: 923-931
        • Cheung C.C.
        • Banerjee D.
        • Barnes P.J.
        • Berendt R.C.
        • Butany J.
        • Canil S.
        • et al.
        Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry.
        Am J Clin Pathol. 2014 Nov; 142: 629-633